Literature DB >> 17632781

A girl with deletion 9q22.1-q22.32 including the PTCH and ROR2 genes identified by genome-wide array-CGH.

Beata Nowakowska1, Anna Kutkowska-Kaźmierczak, Paweł Stankiewicz, Ewa Bocian, Ewa Obersztyn, Zhishuo Ou, Sau Wai Cheung, Wei-Wen Cai.   

Abstract

The underlying genetic cause of mental retardation (MR) remains unknown in about half of the cases. Recently, using whole genome array comparative genomic hybridization (array-CGH), submicroscopic genetic imbalances have been detected in up to 20% of patients with an unexplained MR, dysmorphic features, and apparently normal karyotype. Here, we present a 12-year-old girl with features of basal cell nevus syndrome (BCNS), pulmonary valve stenosis, and MR, in whom array-CGH identified a 7.7 Mb deletion on 9q22.1-q22.32. The deleted region includes, among others, the ROR2 and PTCH genes. Haploinsufficiency of PTCH causes the BCNS syndrome and mutations in ROR2 have been found in an autosomal recessive Robinow syndrome and a dominantly inherited brachydactyly type 1B. We speculate that haploinsufficiency of ROR2 may contribute to pulmonary valve stenosis. Because of an age-dependent penetrance, BCNS may be challenging for diagnosis particularly when the features are not part of a typical clinical spectrum of BCNS. Early diagnosis of BCNS is important for preventing the development of associated tumors and better care of the patient. Our data confirm the previous observations that application of the whole genome array-CGH should be considered in selected patients with undiagnosed MR and dysmorphic features. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632781     DOI: 10.1002/ajmg.a.31845

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  9q22 Deletion--first familial case.

Authors:  Linda Siggberg; Maarit Peippo; Marjatta Sipponen; Taina Miikkulainen; Keiko Shimojima; Toshiyuki Yamamoto; Jaakko Ignatius; Sakari Knuutila
Journal:  Orphanet J Rare Dis       Date:  2011-06-22       Impact factor: 4.123

2.  Clinical utility gene card for: Gorlin syndrome.

Authors:  Lorenzo Lo Muzio; Lorenza Pastorino; Sonja Levanat; Vesna Musani; Mima Situm; Giovanna Bianchi Scarra
Journal:  Eur J Hum Genet       Date:  2011-02-09       Impact factor: 4.246

3.  Clinical utility gene card for: Gorlin syndrome--update 2013.

Authors:  Lorenzo Lo Muzio; Lorenza Pastorino; Sonja Levanat; Vesna Musani; Mima Situm; Giovanni Ponti; Giovanna Bianchi Scarra
Journal:  Eur J Hum Genet       Date:  2013-01-30       Impact factor: 4.246

Review 4.  Novel microdeletion syndromes detected by chromosome microarrays.

Authors:  Anne M Slavotinek
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

5.  PTCH1 duplication in a family with microcephaly and mild developmental delay.

Authors:  Katarzyna Derwińska; Marta Smyk; Mitchell Lance Cooper; Patricia Bader; Sau Wai Cheung; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2008-10-01       Impact factor: 4.246

6.  Copy number variation analysis in single-suture craniosynostosis: multiple rare variants including RUNX2 duplication in two cousins with metopic craniosynostosis.

Authors:  Heather C Mefford; Neil Shafer; Francesca Antonacci; Jesse M Tsai; Sarah S Park; Anne V Hing; Mark J Rieder; Matthew D Smyth; Matthew L Speltz; Evan E Eichler; Michael L Cunningham
Journal:  Am J Med Genet A       Date:  2010-09       Impact factor: 2.802

7.  Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient.

Authors:  Alessandra Morelle; Rodrigo Cericatto; Ana Cristina Victorino Krepischi; Itamar Romano Garcia Ruiz
Journal:  Springerplus       Date:  2014-08-22

8.  Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.

Authors:  Satyabrata Sinha; Ratnesh K Singh; Neyaz Alam; Anup Roy; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  Mol Cancer       Date:  2008-11-06       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.